Patents Assigned to Aventis Behring GmbH
  • Publication number: 20030161837
    Abstract: The present invention relates to a method for the preparation of a conjugate comprising a first and a second polypeptide, said method comprising the steps of (a) incubating said first polypeptide in the presence of a heterobifunctional crosslinker comprising an N-hydroxylsuccinimide ester group and a maleimide group linked via a polyethylene oxide spacer; (b) removing excess heterobifunctional crosslinker; and (c) incubating the reaction product of step (b) with said second polypeptide, wherein said second polypeptide comprises at least one sulfhydryl group. Furthermore, the present invention relates to a conjugate obtainable by the method of the present invention. Also described is a pharmaceutical composition comprising the conjugate of the present invention and, optionally, a pharmaceutically acceptable carrier and/or diluent, and the use of the conjugate for the preparation of a pharmaceutical composition for preventing and/or treating an allergic disease or an autoimmune disease.
    Type: Application
    Filed: February 14, 2003
    Publication date: August 28, 2003
    Applicant: Aventis Behring GmbH
    Inventors: Yves Borel, Werner Schlegel, Erwin Gelfand
  • Publication number: 20030152567
    Abstract: A protease for activating the blood clotting factor VII is described, which
    Type: Application
    Filed: December 16, 2002
    Publication date: August 14, 2003
    Applicant: Aventis Behring GmbH
    Inventors: Juergen Roemisch, Annette Feussner, Hans-Arnold Stoehr
  • Patent number: 6573056
    Abstract: The invention relates to a process for purifying factor VII and/or activated factor VIIa (F VII/F VIIa) by means of binding to immobilized soluble thromboplastin.
    Type: Grant
    Filed: January 25, 2001
    Date of Patent: June 3, 2003
    Assignee: Aventis Behring GmbH
    Inventors: Jürgen Römisch, Hans-Arnold Stöhr, Annette Feussner
  • Patent number: 6573081
    Abstract: Methods for growing circoviruses, in particular porcine circoviruses, which are obtained from an infected cell culture after one or more passages in cultures of porcine, bovine or human cells are described. When the porcine circoviruses grow, a cytopathogenic effect occurs in the cell culture.
    Type: Grant
    Filed: September 7, 2001
    Date of Patent: June 3, 2003
    Assignee: Aventis Behring GmbH
    Inventors: Dieter Bernhardt, Thomas Weimer, Albrecht Groener
  • Patent number: 6537519
    Abstract: The present invention relates to a method for the preparation of a conjugate comprising a first and a second polypeptide, said method comprising the steps of (a) incubating said first polypeptide in the presence of a heterobifunctional crosslinker comprising an N-hydroxylsuccinimide ester group and a maleimide group linked via a polyethylene oxide spacer; (b) removing excess heterobifunctional crosslinker; and (c) incubating the reaction product of step (b) with said second polypeptide, wherein said second polypeptide comprises at least one sulfhydryl group. Furthermore, the present invention relates to a conjugate obtainable by the method of the present invention. Also described is a pharmaceutical composition comprising the conjugate of the present invention and, optionally, a pharmaceutically acceptable carrier and/or diluent, and the use of the conjugate for the preparation of a pharmaceutical composition for preventing and/or treating an allergic disease or an autoimmune disease.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: March 25, 2003
    Assignee: Aventis Behring GmbH
    Inventors: Yves Borel, Werner Schlegel, Erwin Gelfand
  • Patent number: 6528299
    Abstract: A protease for activating the blood clotting factor VII, which is inhibited by the presence of aprotinin, is increased in its activity by calcium ions and/or heparin or heparin-related substances, and in SDS-PAGE, on subsequent staining in the non-reduced state, comprises one or more bands in the molecular weight range from 50 to 75 kDa; and in SDS-PAGE, on subsequent staining in the reduced state, comprises a band at 40 to 55 kDa, one or more bands in the molecular weight range from 10 to 35 kDa, and a band in the molecular weight range between 60 and 65 kDa, which corresponds to a proenzyme. Pharmaceutical preparations containing the protease or its proenzyme are suitable for the prophylaxis and treatment of bleeding events, e.g. in the presence of FVIII inhibitors, wound healing and for the treatment of disorders which are caused by fibrin-containing thrombin.
    Type: Grant
    Filed: April 21, 1999
    Date of Patent: March 4, 2003
    Assignee: Aventis Behring GmbH
    Inventors: Jürgen Römisch, Annette Feussner, Hans-Arnold Stöhr
  • Patent number: 6514940
    Abstract: A stabilized antithrombin III preparation is described which is protected against a loss of action during pasteurization by the addition of stabilizers which consist of one or more saccharides in a mixture with more than 0.5 mol/l of one or more amino acids from the group consisting of arginine, lysine, histidine, phenylalanine, tryptophan, tyrosine, aspartic acid and its salts or glutamic acid and its salts, it also being possible to additionally add glycine or glutamine to each of these amino acids.
    Type: Grant
    Filed: December 7, 1999
    Date of Patent: February 4, 2003
    Assignee: Aventis Behring GmbH
    Inventors: Jürgen Römisch, Harald Stauss
  • Publication number: 20030003096
    Abstract: A monoclonal antibody has been developed which only specifically binds activated factor VII, and not factor VII, and which does not bind to an activated factor VII which is complexed with antithrombin III. This monoclonal antibody is isolated from the hybridoma cell line DSM ACC 2332. It can be used for qualitatively and quantitatively detecting factor VIIa in body fluids, blood coagulation preparations or the intermediate stages in the production of these preparations, on cell surfaces or in tissues, and can also be used as a humanized monoclonal antibody in therapeutic preparations.
    Type: Application
    Filed: August 23, 2002
    Publication date: January 2, 2003
    Applicant: Aventis Behring GmbH.
    Inventors: Sonnenhang Jurgen Romisch, Akazienweg Wiegand Lang, Langewiesenweg Annette Feussner, Hohenweg Joachim Roder
  • Patent number: 6500427
    Abstract: A description is given of a one-component tissue adhesive containing, in aqueous solution, fibrinogen, F XIII, a thrombin inhibitor, prothrombin factors, calcium ions and, where appropriate, a plasmin inhibitor and of a process for the production thereof. This adhesive can be reconstituted from a freeze-dried form with water. It can contain aLL active substances in pasteurized form and is then free of the risk of transmission of hepatitis and HTLV III.
    Type: Grant
    Filed: October 20, 1994
    Date of Patent: December 31, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Norbert Heimburger, Peter Fuhge, Hansjörg Ronneberger
  • Patent number: 6489443
    Abstract: A process for the preparation of a protein solution is described which is not prone to flock or particle formation even on heat treatment, the heat treatment being carried out in a glass vessel which has been rinsed out beforehand with a detergent solution and then with distilled water or another detergent-free solvent.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: December 3, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Jürgen Römisch, Jörg Weisse, Jean Luc Veron, Juliana Djordjevich, Wilfried Freudenberg, Michel Grandgeorge, Barbara Kalina, Peter Kappus, Manfred Konrad, Gregory S. Rood, Werner Thill
  • Publication number: 20020177544
    Abstract: An adenoviral transfer vector for the gene transport of a DNA sequence, which is produced from an adenoviral plasmid which no longer expresses any natural adenoviral proteins and comprises
    Type: Application
    Filed: February 19, 1999
    Publication date: November 28, 2002
    Applicant: AVENTIS BEHRING GMBH
    Inventors: ANJA HAACK, CHRISTOPH SCHMITT
  • Patent number: 6486377
    Abstract: A biodegradable, flexible wound covering based on fibrin and a process for its preparation are described, in which a fibrinogen solution is subjected to a single-stage or multistage dialysis, then a flexible fibrin web is formed by action of an aqueous thrombin solution on the fibrinogen solution and this is subsequently subjected to freeze-drying.
    Type: Grant
    Filed: May 2, 2001
    Date of Patent: November 26, 2002
    Assignee: Aventis Behring GmbH
    Inventor: Mirna Rapp
  • Patent number: 6482590
    Abstract: The present invention relates to a method for selectively extending an oligonucleotide primer along a specific target polynucleotide sequence in a mixture of polynucleotides. Selective extension is achieved by controlling the concentration of the oligonucleotide primer by forming the oligonucleotide in situ by degrading the 3′-end of a modified oligonucleotide. The method comprises providing in combination the mixture of polynucleotides and the modified oligonucleotide having a 3′-end that is not extendable along any polynucleotide and extending the oligonucleotide primer selectively along the specific target polynucleotide sequence by controlling the degradation of the 3′-end of the modified oligonucleotide. In this way extension of the oligonucleotide primer along polynucleotides other than the specific target polynucleotide sequence is substantially reduced or avoided. In another aspect the invention is an improvement in a method for amplifying a target polynucleotide sequence.
    Type: Grant
    Filed: November 6, 1997
    Date of Patent: November 19, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Edwin F. Ullman, Alla Lishanski, Nurith Kurn
  • Patent number: 6479245
    Abstract: A monoclonal antibody has been developed which only specifically binds activated factor VII, and not factor VII, and which does not bind to an activated factor VII which is complexed with antithrombin III. This monoclonal antibody is isolated from the hybridoma cell line DSM ACC 2332. It can be used for qualitatively and quantitatively detecting factor VIIa in body fluids, blood coagulation preparations or the intermediate stages in the production of these preparations, on cell surfaces or in tissues, and can also be used as a humanized monoclonal antibody in therapeutic preparations.
    Type: Grant
    Filed: January 21, 1999
    Date of Patent: November 12, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Jürgen Römisch, Wiegand Lang, Annette Feussner, Joachim Röder
  • Publication number: 20020164596
    Abstract: A process for finding heterologous oligonucleotide sequences for a nucleic acid amplification method is described, in which process
    Type: Application
    Filed: April 13, 2001
    Publication date: November 7, 2002
    Applicant: AVENTIS BEHRING GMBH
    Inventor: Thomas Weimer
  • Publication number: 20020164323
    Abstract: Pharmaceutical preparation for the treatment of inflammatory processes A pharmaceutical preparation is described while is useful for the treatment of inflammatory processes being accompanied by an increased distribution of cytokines and/or tissue factor in the human body, which preparation contains Antithrombin III as active ingredient.
    Type: Application
    Filed: April 23, 2002
    Publication date: November 7, 2002
    Applicant: Aventis Behring GmbH
    Inventors: Jurgen Romisch, Gerhard Dickneite, Peter Gronski, Bernhard Vohwinkel, Harald Stauss, Elaine Gray, Pauline Sxouter, Stephen Poole
  • Publication number: 20020165177
    Abstract: A modified Factor VIII cDNA is described in which the B-domain of the wild-type Factor VIII cDNA has been deleted and a truncated Factor IX intron 1 has been inserted in one or more locatons of the Factor VIII cDNA. Such modified Factor VIII cDNA may be used for a higher yield production of Factor VIII in vitro as well as in a transfervector for gene therapy.
    Type: Application
    Filed: June 15, 2001
    Publication date: November 7, 2002
    Applicant: Aventis Behring GmbH, a German company
    Inventors: Claude Negrier, Jean Luc Plantier
  • Patent number: 6468778
    Abstract: A process for the inactivation and/or elimination of coated and/or noncoated viruses from a plasma protein solution by addition of an ammonium salt at alkaline pHs is described, in which a chromatographically prepurified plasma protein solution is subjected to an incubation at room temperature and at an ammonium salt concentration of 13 to 22% by weight, pasteurized at approximately 60° C. for several hours after separation of the precipitates and removal of the ammonium salt down to a residual content of less than 0.5 mol/l and then processed to give a therapeutically employable plasma protein preparation.
    Type: Grant
    Filed: May 17, 2000
    Date of Patent: October 22, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Eckhard Schueler, Gerhardt Kumpe, Thomas Nowak
  • Patent number: 6450681
    Abstract: The invention proposes a process and an arrangement for dissolving albumin flakes in a liquid which is filled into a container. In the process according to the invention, it is intended that the flakes are moved relative to the liquid. The arrangement for carrying out the process has a constructional embodiment which permits a number of containers (6) to be treated simultaneously by the process according to the invention, the arrangement having one or more motors (10) for driving the construction elements (3, 4, 7, 8, 9), which move the containers (6 ) in a rotary or translational motion during the treatment.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: September 17, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Hubert Nettelhoff, Jürgen Römisch
  • Patent number: 6447774
    Abstract: A tissue adhesive is described, which contains three separate components, i.e., a stabilized, essentially fibrinogen-free protein preparation that is of storage-quality in liquid state and contains the blood coagulation factor XIII a stabilized protein preparation that is of storage-quality in liquid state and contains fibrinogen. A chaotropic substance of less than 0.28 mol/liter was added to said protein preparation to avoid or reduce the aggregation of fibrinogen, and a preparation containing thrombin, which are provided in one packaging unit prepared to be used together. Furthermore, stabilized, frozen or lyophilized protein preparations containing fibrinogen and Factor XIII are described. Said protein preparations contain fibrinogen- and Factor XIII which remains stable for more than four weeks after defrosting or reconstitution, as well as one or more added chaotropic substances in a quantity of less than 0.
    Type: Grant
    Filed: July 13, 2001
    Date of Patent: September 10, 2002
    Assignee: Aventis Behring GmbH
    Inventors: Hubert Metzner, Peter Gronski